JP2002520418A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002520418A5 JP2002520418A5 JP2000560136A JP2000560136A JP2002520418A5 JP 2002520418 A5 JP2002520418 A5 JP 2002520418A5 JP 2000560136 A JP2000560136 A JP 2000560136A JP 2000560136 A JP2000560136 A JP 2000560136A JP 2002520418 A5 JP2002520418 A5 JP 2002520418A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- phenyl
- formula
- substituted
- hydrogen atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 30
- 150000001875 compounds Chemical class 0.000 description 29
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 23
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 22
- 125000000217 alkyl group Chemical group 0.000 description 13
- 125000001072 heteroaryl group Chemical group 0.000 description 10
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- -1 phenyl - Chemical class 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 208000012659 Joint disease Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 150000002390 heteroarenes Chemical class 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 208000018083 Bone metabolism disease Diseases 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- LUHNDNBRKDWRDN-UHFFFAOYSA-N CC(C)(C(C1=CC=C(C(F)(F)F)C=C1)NS(C(C=C1)=CC=C1C(C=C1)=CC=C1Cl)(=O)=O)C(O)OP(O)=O Chemical compound CC(C)(C(C1=CC=C(C(F)(F)F)C=C1)NS(C(C=C1)=CC=C1C(C=C1)=CC=C1Cl)(=O)=O)C(O)OP(O)=O LUHNDNBRKDWRDN-UHFFFAOYSA-N 0.000 description 1
- JMRDNPFCGLMHOW-UHFFFAOYSA-N CCN(CC)C(SCI)=C Chemical compound CCN(CC)C(SCI)=C JMRDNPFCGLMHOW-UHFFFAOYSA-N 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- BVMWIXWOIGJRGE-UHFFFAOYSA-N NP(O)=O Chemical compound NP(O)=O BVMWIXWOIGJRGE-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- BUKCBCDGRPOFJP-MRXNPFEDSA-N [(1r)-1-[[4-(4-chlorophenyl)phenyl]sulfonylamino]-2-methylpropyl]phosphonic acid Chemical compound C1=CC(S(=O)(=O)N[C@@H](C(C)C)P(O)(O)=O)=CC=C1C1=CC=C(Cl)C=C1 BUKCBCDGRPOFJP-MRXNPFEDSA-N 0.000 description 1
- IYAITALWHDVINW-UHFFFAOYSA-N [1-[[4-(4-chlorophenyl)phenyl]sulfonylamino]-3-methylbutyl]phosphonic acid Chemical compound C1=CC(S(=O)(=O)NC(CC(C)C)P(O)(O)=O)=CC=C1C1=CC=C(Cl)C=C1 IYAITALWHDVINW-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000004417 patella Anatomy 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical compound O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19831980.0 | 1998-07-16 | ||
| DE19831980A DE19831980A1 (de) | 1998-07-16 | 1998-07-16 | Sulfonylaminophosphin- und phosphonsäurederivate |
| DE19921680A DE19921680A1 (de) | 1999-05-12 | 1999-05-12 | Sulfonylaminophosphin- und phosphonsäurederivate |
| DE19921680.0 | 1999-05-12 | ||
| PCT/EP1999/004740 WO2000004030A1 (de) | 1998-07-16 | 1999-07-07 | Phosphin- und phosphonsäurederivate als arzneimittel |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002520418A JP2002520418A (ja) | 2002-07-09 |
| JP2002520418A5 true JP2002520418A5 (cg-RX-API-DMAC7.html) | 2006-08-10 |
| JP4567886B2 JP4567886B2 (ja) | 2010-10-20 |
Family
ID=26047473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000560136A Expired - Fee Related JP4567886B2 (ja) | 1998-07-16 | 1999-07-07 | 医薬として使用されるホスフィン酸およびホスホン酸誘導体 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US6235727B1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1097159B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4567886B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR100615345B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN1194978C (cg-RX-API-DMAC7.html) |
| AR (1) | AR019390A1 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE227295T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU754050B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR9912085A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2337828C (cg-RX-API-DMAC7.html) |
| CZ (1) | CZ300780B6 (cg-RX-API-DMAC7.html) |
| DE (1) | DE59903329D1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1097159T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2187171T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUP0102837A3 (cg-RX-API-DMAC7.html) |
| ID (1) | ID27133A (cg-RX-API-DMAC7.html) |
| PL (1) | PL199234B1 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1097159E (cg-RX-API-DMAC7.html) |
| RU (1) | RU2224762C2 (cg-RX-API-DMAC7.html) |
| TR (1) | TR200100084T2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2000004030A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001002411A1 (en) * | 1999-07-06 | 2001-01-11 | Methylgene Inc. | SULFONAMIDOMETHYL PHOSPHONATE INHIBITORS OF β-LACTAMASE |
| MXPA05001544A (es) * | 2002-08-08 | 2005-04-19 | Smithkline Beecham Corp | Compuestos de tiofeno. |
| JP4450192B2 (ja) | 2004-07-01 | 2010-04-14 | 信越化学工業株式会社 | 珪素複合体及びその製造方法並びに非水電解質二次電池用負極材 |
| AU2007268081A1 (en) * | 2006-05-22 | 2007-12-06 | Methylgene Inc. | Novel sulfonamidomethylphosphonate inhibitors of beta-lactamase |
| AU2007332968B2 (en) * | 2006-05-22 | 2013-07-11 | Methylgene Inc. | Novel inhibitors of beta-lactamase |
| JP5399219B2 (ja) * | 2009-11-24 | 2014-01-29 | 株式会社ケイティーバイオ | 関節リウマチに対するヒト型抗TNFα抗体薬の薬効予測方法、及び薬効予測装置 |
| CN108676031A (zh) * | 2018-05-29 | 2018-10-19 | 重庆威鹏药业有限公司 | 水溶性三唑类抗真菌膦酸化合物及其制备方法和应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3996040A (en) * | 1974-06-28 | 1976-12-07 | Monsanto Company | Increasing sucrose content of sugar cane employing N-phenylsulfonamido-N-phosphonomethyl glycine and certain derivatives thereof |
| JPS6137800A (ja) * | 1984-07-31 | 1986-02-22 | Kyowa Hakko Kogyo Co Ltd | 含リンペプチド |
| DE3435156A1 (de) * | 1984-09-25 | 1986-04-03 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren zur herstellung der stereoisomeren von 1-amino-alkylphosphonsaeuren oder 1-aminoalkylphosphinsaeuren |
| JPS62148493A (ja) * | 1985-12-24 | 1987-07-02 | Teijin Ltd | 新規ホスホン酸誘導体および除草剤 |
| EP0243173B1 (en) * | 1986-04-24 | 1991-06-26 | Fujisawa Pharmaceutical Co., Ltd. | New diphosphonic acid compounds, processes for the preparation thereof and pharmaceutical composition comprising the same |
| JP2764262B2 (ja) | 1987-08-28 | 1998-06-11 | 持田製薬株式会社 | ヒダントイン誘導体及びそれを有効成分とする医薬組成物 |
| TW201303B (cg-RX-API-DMAC7.html) | 1990-07-05 | 1993-03-01 | Hoffmann La Roche | |
| JP2525977B2 (ja) * | 1991-10-17 | 1996-08-21 | 昭和電工株式会社 | N−アシルアミノメチルホスホン酸の製造法 |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| AU690703B2 (en) | 1994-06-22 | 1998-04-30 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| KR980009238A (ko) * | 1995-07-28 | 1998-04-30 | 우에노 도시오 | 설포닐아미노산 유도체 |
| CZ294063B6 (cs) * | 1996-05-17 | 2004-09-15 | Warner-Lambert Company | Bifenylsulfonamid, jeho použití a farmaceutický prostředek s jeho obsahem |
| EP0958283A1 (de) * | 1997-01-27 | 1999-11-24 | Nycomed Austria GmbH | Neue verbindungen mit hämoregulatorischer wirkung |
| AU7294098A (en) * | 1997-05-09 | 1998-11-27 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
| ATE210639T1 (de) * | 1997-05-09 | 2001-12-15 | Hoechst Ag | Substituierte diaminocarbonsäuren |
| DE19719621A1 (de) * | 1997-05-09 | 1998-11-12 | Hoechst Ag | Sulfonylaminocarbonsäuren |
-
1999
- 1999-07-07 EP EP99932841A patent/EP1097159B1/de not_active Expired - Lifetime
- 1999-07-07 WO PCT/EP1999/004740 patent/WO2000004030A1/de not_active Ceased
- 1999-07-07 DK DK99932841T patent/DK1097159T3/da active
- 1999-07-07 HU HU0102837A patent/HUP0102837A3/hu unknown
- 1999-07-07 ID IDW20010108A patent/ID27133A/id unknown
- 1999-07-07 AU AU49082/99A patent/AU754050B2/en not_active Ceased
- 1999-07-07 DE DE59903329T patent/DE59903329D1/de not_active Expired - Lifetime
- 1999-07-07 CN CNB998086681A patent/CN1194978C/zh not_active Expired - Fee Related
- 1999-07-07 TR TR2001/00084T patent/TR200100084T2/xx unknown
- 1999-07-07 RU RU2001104433/04A patent/RU2224762C2/ru not_active IP Right Cessation
- 1999-07-07 KR KR1020017000698A patent/KR100615345B1/ko not_active Expired - Fee Related
- 1999-07-07 CA CA2337828A patent/CA2337828C/en not_active Expired - Fee Related
- 1999-07-07 AT AT99932841T patent/ATE227295T1/de not_active IP Right Cessation
- 1999-07-07 PT PT99932841T patent/PT1097159E/pt unknown
- 1999-07-07 JP JP2000560136A patent/JP4567886B2/ja not_active Expired - Fee Related
- 1999-07-07 BR BR9912085-2A patent/BR9912085A/pt not_active Application Discontinuation
- 1999-07-07 CZ CZ20010144A patent/CZ300780B6/cs not_active IP Right Cessation
- 1999-07-07 PL PL345653A patent/PL199234B1/pl not_active IP Right Cessation
- 1999-07-07 ES ES99932841T patent/ES2187171T3/es not_active Expired - Lifetime
- 1999-07-14 AR ARP990103449A patent/AR019390A1/es active IP Right Grant
- 1999-07-15 US US09/353,086 patent/US6235727B1/en not_active Expired - Lifetime
-
2001
- 2001-03-20 US US09/811,698 patent/US6500811B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101142583B1 (ko) | 히알루론산 유도체 및 그것을 포함하는 약제 | |
| KR101262400B1 (ko) | 아미노카르복실산 유도체 및 그 의약 용도 | |
| RU98108979A (ru) | Сульфониламинокарбоновые кислоты | |
| FR2518088A1 (fr) | Nouveaux derives d'aminoacides, et leur application therapeutique | |
| CA2237099A1 (en) | Sulfonylaminocarboxylic acids | |
| JP2002522443A5 (cg-RX-API-DMAC7.html) | ||
| RU2001106614A (ru) | Растворимые в воде пролекарства из затрудненных спиртов или фенолов | |
| RU95113148A (ru) | Производное 2-(2-амино-1,6-дигидро-6-оксопурин-9-ил)-метокси-1,3-пропандиола | |
| RU2005106259A (ru) | Производные пиразола, лекарственные композиции, содержащие эти производные, их применение в медицине и промежуточные соединения для их получения | |
| FR2515039A1 (fr) | Sels de l'acide sulfodehydroabietique et leur utilisation pour le traitement de maladies gastro-intestinales | |
| EP2240501B1 (fr) | Derives d'acide hydroxy-bisphosphonique comme vecteur ciblant le tissu osseux | |
| RU98109049A (ru) | Замещенные 6- и 7-аминотетрагидроизохинолин-карбоновые кислоты | |
| FR2934267A1 (fr) | Derives aminophosphiniques utiles dans le traitement de la douleur | |
| EP1485391B1 (en) | Phosphate transport inhibitors | |
| JPH09508364A (ja) | イノシトール燐酸のバイオアベイラビリティを向上させた薬剤組成物 | |
| RU2001115706A (ru) | Омега-амиды n-арилсульфонил-аминокислот | |
| JP2002529447A5 (cg-RX-API-DMAC7.html) | ||
| JPH05500969A (ja) | テトラ―アザ大環状化合物、それらの調製法およびそれらの磁気共鳴画像形成での使用 | |
| CA2337828A1 (en) | Phosphinic and phosphonic acid derivatives used as pharmaceuticals | |
| RU2001104433A (ru) | Производные фосфиновой и фосфоновой кислот в качестве лекарственных средств | |
| PT1913009E (pt) | Novos (tio)carbamatos de benzimidazole com actividade antiparasitária e sua síntese | |
| JP4733270B2 (ja) | インターロイキン−1−βインヒビターとしての置換されたチアジアゾールスルホンアミド | |
| CA2416015A1 (en) | Matrix metalloproteinase inhibitors | |
| KR100718030B1 (ko) | 변형성 관절증 치료제 | |
| JPH01319466A (ja) | バクロフェン誘導体、およびこれを含有する医薬品 |